Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

Inclusion Criteria: * Is infected with HIV * Is receiving combination anti-retroviral therapy (ART) for ≥6 weeks before study entry with no intended changes to combination ART therapy for 3 months after randomization. * Is vaccine-naïve Exclusion Criteria: * Has a history of opportunistic infections ≤12 months before the first vaccination * Has a history of noninfectious acquired immune deficiency syndrome-related illness * Has a history of active hepatitis * Has a history of invasive pneumococcal disease (IPD) or other culture-positive pneumococcal disease ≤3 years before Visit 2 (Day 1) * Has a known hypersensitivity to any component of V116, PCV15, or PPSV23, including diphtheria toxoid * Has a known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease * Has a coagulation disorder contraindicating intramuscular vaccinations. * Has a recent illness with fever * Has a known cancer malignancy that is progressing or has required active treatment \<3 years before enrollment * Had prior administration of PCV15 or PCV20. * Is expected to receive any pneumococcal vaccine during the study outside of the protocol * Has received systemic corticosteroids for ≥14 consecutive days and has not completed treatment ≥14 days before receipt of study vaccine * Is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interv…